N/A N=106 The Role of Apathy in Glycemic Control
Apathy · Diabetes
Primary: Change in HbA1c Over Baseline — -1.0; -0.1 percentage of HbA1c
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Botulinum Toxin in the Treatment of Raynaud's
Raynaud's Syndrome
Primary: Mean Digital Temperature Difference From Baseline — 1.30 Celsius
Phase 2 N=16 Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
Extensive-Stage Small Cell Lung Cancer
Primary: Progression Free Survival Rate — 13 percentage of patients with PFS
Phase 3 N=936 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c After 30 Weeks of Treatment. — -0.66; -0.69; -0.87; -0.39 percent — p=0.1571
Phase 2 N=374 Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
Cervical Ripening · Induction of Labor
Primary: Proportion of Women Delivering Vaginally — 63.75; 66.67; 76.00 percentage of participants — p=0.057
Phase 2 N=2 Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants With a Reduction of HbA1c of >0.5% — 0; 0 Participants
Phase 3 N=570 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12. — 10.83; 10.90; -4.13; -2.71 Hot flashes per day — p=<0.0001
Phase 3 N=251 Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All…
N/A N=60 ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation
ADHD · ADD
Primary: Clinical Assessment (Amen Questionnaire) — 9.85; 3.55; 5.15; 3.54 units on a scale
Phase 3 N=180 A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection
Chronic Hepatitis B Virus, Pediatric
Primary: Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 — 24.4; 2.4…
N/A N=71 A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Rheumatoid Arthritis
Primary: Change in Overall Health Assessment Questionnaire Disability Index (HAQ-DI) Scores From Baseline to 6 Months — -0.41 units on a scale
Phase 2 N=160 LT Vaccine Patch Self-Administration Study
Prevention of Travelers' Diarrhea
Primary: GMTs After a Self-administered LT Vaccine Patch (In-clinic or Away From Clinic) Compared to a Clinician-administered LT Vaccine Patch. — 362; 442; 1974; 2896 geometric…
Phase 4 N=49 The Muscle Relaxation-study
Cholecystectomy, Laparoscopic
Primary: The Percentage of Patients With Optimal Surgical Space Conditions ( 1 at a 4-step Scale) Assessed at the Time During Surgery, When View Was Less — 28; 4 percentage of…
Phase 2 N=120 Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants
Infections, Streptococcal
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms and Grade 3 Solicited Local Symptoms With Relationship to Vaccination - For Step 1/Cohort 1 Subjects…
Phase 2 N=80 Efficacy and Safety of Actiponin on Antiobesity in Obese Korean Subjects.
Obesity
Primary: Changes in Body Fat Mass. — 22.65; 23.04; 22.28; 23.17 kg — p=<0.05